Clinical trial

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated…

NCT00289627 · Bristol-Myers Squibb, Industry · Completed

Key facts

NCT number NCT00289627
Title A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Official title A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Lead sponsor Bristol-Myers Squibb, Industry
Collaborators Medarex Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Melanoma
Intervention type Drug
Interventions ipilimumab (MDX-010, BMS-734016)
Enrollment 155
Start date Apr 1, 2006
Primary completion Jul 1, 2007
Completion Jul 1, 2007
First posted Feb 10, 2006
Last update posted Sep 28, 2016
Countries Austria, Finland, Italy, Norway, Poland, Russia, Spain, Sweden, Ukraine, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies